Explore 4-Hydroxy-N,N-diisopropyltryptamine

TiHKAL book II entry 4-HO-DIPT

ChemSpider 10579819
PubChem 21854225
Wikidata Q229960
Erowid 4-Hydroxy-DIPT
Wikipedia 4-HO-DiPT
Blotter 4-HO-DIPT
PsychonautWiki 4-HO-DiPT
Project Response 4-Hydroxy-DiPT (1471-16)
bluelight.org The Big & Dandy 4-HO-DiPT Thread
swgdrug.org 4-Hydroxy-DIPT
bluelight.org 4-HO-DiPT Effects and Ratings Survey Results

TiHKAL #15 4-HO-DBT

Repke, DB; Ferguson, WJ; Bates, DK. Psilocin analogs. 1. Synthesis of 3-[2-(dialkylamino)ethyl]- and 3-[2-(cycloalkylamino)ethyl]indol-4-ols. J. Heterocycl. Chem., 1 Jan 1977, 14 (1), 71–74. 273 kB. https://doi.org/10.1002/jhet.5570140113 #4d NMR

Rodriguez-Cruz, SE. Analysis and characterization of designer tryptamines using electrospray ionization mass spectrometry (ESI-MS). Microgram J., 1 Jul 2005, 3 (3–4), 107–129. 1.6 MB.

Dinger, J; Woods, C; Brandt, SD; Meyer, MR; Maurer, HH. Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol. Lett., 1 Jan 2016, 241, 82-94. 2.6 MB. https://doi.org/10.1016/j.toxlet.2015.11.013

Meyer, MR; Caspar, A; Brandt, SD; Maurer, HH. A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 β-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches. Anal. Bioanal. Chem., 1 Jan 2014, 406 (1), 225–237. 457 kB. https://doi.org/10.1007/s00216-013-7425-9 #4-HO-DIPT LC,MS

Brandt, SD; Martins, CPB. Analytical methods for psychoactive N,N-dialkylated tryptamines. Trends Anal. Chem., 1 Sep 2010, 29 (8), 858–869. 446 kB. https://doi.org/10.1016/j.trac.2010.04.008 #20

Chapman, SJ. PeakAL: Protons I Have Known and Loved, Too — Another Fifty Shades of Grey-Market Spectra. BLOTTER, 1 Mar 2018, 3 (1). 1.2 MB. https://doi.org/10.16889/isomerdesign-5

Chapman, SJ. PeakAL: Protons I Have Known and Loved, Too — Another Fifty Shades of Grey-Market Spectra. Supplementary Data. BLOTTER, 1 Mar 2018, 3 (1). 5.7 MB. https://doi.org/10.16889/isomerdesign-5-supp

Zhang, S; Fan, Y; Shi, Z; Cheng, S. DFT-based QSAR and action mechanism of phenylalkylamine and tryptamine hallucinogens. Chin. J. Chem., 1 Apr 2011, 29 (4), 623–630. 166 kB. https://doi.org/10.1002/cjoc.201190132 #71

Rickli, A; Moning, OD; Hoener, MC; Liechti, ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur. Neuropsychopharmacol., 1 Aug 2016, 26 (8), 1327-1337. 845 kB. https://doi.org/10.1016/j.euroneuro.2016.05.001

Jacob, P; Shulgin, AT. Structure-activity relationships of the classic hallucinogens and their analogs. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 74–91. 51 kB.

Shulgin, AT. Basic Pharmacology and Effects. In Hallucinogens. A Forensic Drug Handbook; Laing, R; Siegel, JA, Eds., Academic Press, London, 24 Apr 2003; pp 67–137. 6.3 MB.

Shulgin, AT. Chemistry of psychotomimetics. In Handbook of Experimental Pharmacology. Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs; Hoffmeister, F; Stille, G, Eds., Springer-Verlag, Berlin, 1 Jan 1982; Vol. 55 (3), pp 3–29. 928 kB. https://doi.org/10.1007/978-3-642-67770-0_1 #4k

Takahashi, M; Nagashima, M; Suzuki, J; Seto, T; Yasuda, I; Yoshida, T. Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry. Talanta, 15 Feb 2009, 77 (4), 1245–1272. 1.2 MB. https://doi.org/10.1016/j.talanta.2008.07.062 #4-HO-DIPT

EMCDDA. New drugs in Europe, 2005, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2006. 1.2 MB. #4-HO-DIPT

Zamberlan, F; Sanz, C; Vivot, RM; Pallavicini, C; Erowid, F; Erowid, E; Tagliazucchi, E. The varieties of the psychedelic experience: A preliminary study of the association between the reported subjective effects and the binding affinity profiles of substituted phenethylamines and tryptamines. Front. Integr. Neurosci., 8 Nov 2018, 12 (54). 5.0 MB. https://doi.org/10.3389/fnint.2018.00054 #4-OH-DIPT

Luethi, D; Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int. J. Neuropsychoph., 1 Oct 2018, 21 (10), 926–931. 254 kB. https://doi.org/10.1093/ijnp/pyy047 #S2 Tryptamines 4-OH-DiPT

Halberstadt, AL; Chatha, M; Klein, AK; Wallach, J; Brandt, SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology, 1 May 2020, 167, 107933. 2.4 MB. https://doi.org/10.1016/j.neuropharm.2019.107933 #4-HO-DIPT

Sexton, JD; Nichols, CD; Hendricks, PS. Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics. Front. Psychiatry, 11 Feb 2020, 10 (896). 529 kB. https://doi.org/10.3389/fpsyt.2019.00896 #4-HO-DiPT

Flanagan, TW; Billac, GB; Landry, AN; Sebastian, MN; Cormier, SA; Nichols, CD. Structure–activity relationship analysis of psychedelics in a rat model of asthma reveals the anti-inflammatory pharmacophore. ACS Pharmacol. Transl. Sci., 9 Apr 2021, 4 (2), 488-502. 13.3 MB. https://doi.org/10.1021/acsptsci.0c00063 #4-OH-DIPT

Klein, AK; Chatha, M; Laskowski, LJ; Anderson, EI; Brandt, SD; Chapman, SJ; McCorvy, JD; Halberstadt, AL. Investigation of the structure–activity relationships of psilocybin analogues. ACS Pharmacol. Transl. Sci., 9 Apr 2021, 4 (2), 533-542. 1.9 MB. https://doi.org/10.1021/acsptsci.0c00176 #4-HO-DIPT

Kikura-Hanajiri, R; Kawamura, M; Uchiyama, N; Ogata, J; Kamakura, H; Saisho, K; Goda, Y. Analytical data of designated substances (shitei-yakubutsu) controlled by the pharmaceutical affairs law in Japan, Part I: GC-MS and LC-MS. Yakugaku Zasshi, 1 Jun 2008, 128 (6), 971–979. 1.4 MB. https://doi.org/10.1248/yakushi.128.971 #4-OH-DIPT Incorrect structures drawn. Corrected structures in errata page at end. GC,LC,MS,UV

Uchiyama, N; Kawamura, M; Kamakura, H; Kikura-Hanajiri, R; Goda, Y. Analytical data of designated substances (shitei-yakubutsu) controlled by the pharmaceutical affairs law in Japan, Part II: Color test and TLC. Yakugaku Zasshi, 1 Jan 2008, 128 (6), 981–987. 406 kB. https://doi.org/10.1248/yakushi.128.981 #4-OH-DIPT TLC

Naeem, M; Bauer, BE; Chadeayne, AR; Golen, JA; Manke, DR. The methanol and ethanol solvates of 4-glutarato-N,N-diisopropyltryptamine. Acta Crystallogr. E, 1 Oct 2022, 78 (10), 1034–1038. 749 kB. https://doi.org/10.1107/S2056989022009094 #4-HO-DIPT NMR,other

McKenna, DJ; Towers, HHN. Biochemistry and pharmacology of tryptamines and beta-carbolines: A minireview. J. Psychoactive Drugs, 1 Jan 1984, 16 (4), 347–358. 10.8 MB. https://doi.org/10.1080/02791072.1984.10472305 #4-Hydroxy-diisopropyl-tryptamine

4-HO-DPT · 4-Hydroxy-N,N-dipropyltryptamine

1-Isopropyl-5-MeO-DMT · 1-Isopropyl-5-methoxy-N,N-dimethyltryptamine

5-MeO-EIPT · 5-Methoxy-N-ethyl-N-isopropyltryptamine

5-HO-DIPT · 5-Hydroxy-N,N-diisopropyltryptamine

5-MeO-EPT · 5-Methoxy-N-ethyl-N-propyltryptamine

5-EtO-MIPT · 5-Ethoxy-N-methyl-N-isopropyltryptamine

5-EtO-MPT · 5-Ethoxy-N-methyl-N-propyltryptamine

5-EtO-DET · 5-Ethoxy-N,N-diethyltryptamine

2-Methyl-5-MeO-MIPT · 2-Methyl-5-methoxy-N-methyl-N-isopropyltryptamine

2-Methyl-5-MeO-DET · 2-Methyl-5-methoxy-N,N-diethyltryptamine

5-MeO-MIBT · 5-Methoxy-N-methyl-N-isobutyltryptamine

5-HO-DPT · 5-Hydroxy-N,N-dipropyltryptamine

5-MeO-MBT · 5-Methoxy-N-methyl-N-butyltryptamine

2-Propyl-5-MeO-DMT · 2-Propyl-5-methoxy-N,N-dimethyltryptamine

1-Propyl-5-MeO-DMT · 1-Propyl-5-methoxy-N,N-dimethyltryptamine

5-Hexyloxy-T · 5-Hexyloxytryptamine

5-Pentyloxy-N-methyltryptamine · 5-Pentyloxy-NMT

N-Methyl-butyrylfentanyl

N,N-Dipropyltryptamine N-oxide · DPT N-oxide

4-HO-PIPT · 4-Hydroxy-N-propyl-N-isopropyltryptamine

U13

A13 · AH-7563

p2-293: 4-HO-DIPT